Business Wire

EFFEPHARM-LTD

7.6.2022 11:15:13 CEST | Business Wire | Press release

Share
Effepharm's UTHEVER® NMN: 66 people Human Clinical Trial Data Published, NAD+/NADH Level increased 38% in 2 months

Effepharm Ltd creatively launched a branded NMN ingredient to bring the purest and safest NMN ingredient around the world. UTHEVER® NMN has been clinically proven to be safe and to improve the NAD+/NADH level in the human body, thus realizing the anti-aging function.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005649/en/

On 5th May 2022, Frontiers in Aging, an authoritative international journal on aging mechanisms, published one NMN clinical trial report with new insights and more experience being brought into the field of longevity.

Frontiers in Aging, one of the largest and highest-cited publishers in the world, led and peer-reviewed by editorial boards of over 100,000 top researchers, agreed to publish UTHEVER® NMN’s human clinical trial report , which was reviewed by scientists, including professors at Harvard Medical School. This is the first time that Effepharm released detailed trial data to the public.

Compared with previous NMN clinical trials involving dozens of people, the number of Effepharm’s UTHEVER® clinical trial was up to 66 people which is more conspicuous. At the end of the study (day 60), the level of NAD+/NADH increased further by 38% from baseline in the UTHEVER® group, compared to a mere 14.3% rise in the placebo group which might be attributed to the placebo effect. HOMA (homeostatic model assessment), 6 minute walking endurance test and SF-36 questionnaire were assessed to show that UTHEVER® has the potential to improve the quality of life and boost the happiness of the subjects under the test conditions.

Moreover, Effepharm as one of the leading manufacturer of NMN, has finished the toxicology tests of Uthever, which proved that Uthever is non-mutagenic and has no acute and sub-chronic toxicity. Although the test results are not publicly available now, they have laid a solid foundation for the evaluation of the safety of UTHEVER® NMN.

Effepharm’s R&D Director Jianjun Yu said: “ The clinical trials of UTHEVER® NMN is to establish a more professional and scientific image, helping the downstream supplement brand side get more power to do product endorsement and give more confidence to end consumers. Up to now, more and more well-known supplement brands such as Prohealth Longevity® in the USA, Do Not Age in UK, Kenay® Agescience, AFEGE Anti-aging Shop, MoleQlar in EU., VitaNAD+ in Japan etc. are using UTHEVER® trademark and realized the co-branding effects.”

Dr. Yu also revealed that the first period of NMN clinical trials mainly aimed to verify the safety of UTHEVER® NMN, so we designed a lower dosage to some extent. In the next few years, we will consider to conduct more NMN function researches to explore the safety of larger doses of NMN and the effectiveness of related indications on which this trial data are based. Effepharm Ltd will also apply for FDA Affirmed GRAS on NMN, which means that NMN raw material through the food regulations of various countries has taken a milestone step.

Reference:

https://www.frontiersin.org/articles/10.3389/fragi.2022.851698/full

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release

Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release

European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res

Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release

Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work

Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release

Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf

New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release

New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye